Abstract
Bladder cancer is a common malignancy for which regional or metastatic disease is identified at diagnosis. The aim of this study was to determine whether tamoxifen (Tam), an estrogen receptor (ER) antagonist, can sensitize bladder cancer cell lines to gemcitabine (Gem) chemotherapy. ERα and ERβ protein levels were determined in each cell line using western blot analysis. The TCC-Sup, 5637, and RT4 bladder cancer cells were exposed to various concentrations and regimens of Tam or Gem alone or in combination. Cell viability and apoptosis were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and propidium iodide followed by flow cytometry. Apoptosis was then evaluated by western blot analysis. Treated TCC-Sup cells were subjected to soft agar colony formation assay to determine the cellular transformation. Western blot analysis results revealed ER expression in the three cell lines. TCC-Sup and 5637 cells treated with a combination of Tam and Gem had lower cell viabilities than those treated with Tam or Gem alone for 72 h in TCC-Sup and 5637. Compared with the other treatments, sequential Gem followed by Tam (Gem→Tam) treatment caused the largest increase in DNA fragmentation at 72 h in TCC-Sup cells....Continue Reading
References
Dec 15, 1989·Cancer·C N SternbergN Bander
May 2, 1998·Science·E Marshall
Sep 23, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H von der MaaseP F Conte
Dec 23, 2000·The Journal of Urology·C Pfister
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HussainD C Smith
Oct 3, 2001·Physiological Reviews·S NilssonJ A Gustafsson
Jun 11, 2005·The Journal of Urology·Jonathan E RosenbergEric J Small
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Mar 25, 2006·Molecular Endocrinology·Heather A Harris
May 16, 2006·Cancer·Steven S ShenSeth P Lerner
Mar 17, 2007·Endocrinology·Aiping ZhengPirkko Härkönen
Nov 27, 2007·The Breast : Official Journal of the European Society of Mastology·Nicola SilvestrisVito Lorusso
Apr 18, 2009·Urologic Oncology·Can TuygunNurettin Sertcelik
Jul 14, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hiltrud Brauch, V Craig Jordan
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Nov 19, 2011·International Journal of Pharmaceutics·D CoscoM Fresta
Jan 10, 2012·BJU International·Hiroshi MiyamotoShuyuan Yeh
Jan 13, 2012·World Journal of Urology·Bangmin HanShujie Xia
Nov 24, 2012·Cell Death and Differentiation·G G JineshA M Kamat
May 31, 2013·Cancer·Matthew D GalskyAristotle Bamias
Feb 15, 2014·Cancer Cell·Woonyoung ChoiDavid J McConkey
Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Citations
Jun 29, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Feihu JiTingmei Chen
Apr 22, 2017·Anti-cancer Drugs·Xiao-Long HuangWei-Yang He
Apr 5, 2016·Scientific Reports·Goodwin G JineshAshish M Kamat
Mar 12, 2017·Apoptosis : an International Journal on Programmed Cell Death·Rikiya TaokaAshish M Kamat
Nov 30, 2018·Virchows Archiv : an International Journal of Pathology·Philipp ErbenUNKNOWN BRIDGE Consortium e.V.
Oct 13, 2020·Biomolecules & Therapeutics·Huihui ZhuJingji Jin
Apr 3, 2021·Frontiers in Endocrinology·Takuro Goto, Hiroshi Miyamoto
Jun 3, 2021·Cells·Hiroki Ide, Hiroshi Miyamoto
Jul 24, 2021·Oncology Reports·Junhao LinWei Li
Sep 29, 2021·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Josephine M Hyldgaard, Jørgen Bjerggaard Jensen